Studies with ZD1839 in preclinical models

被引：78

作者：

Sirotnak, FM

机构：

[1] Mem Sloan Kettering Canc Ctr, Lab Mol Therapeut, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, New York, NY 10021 USA

来源：

SEMINARS IN ONCOLOGY | 2003年 / 30卷 / 01期

关键词：

D O I：

10.1053/sonc.2003.50028

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：12 / 20

页数：9

共 50 条

[1]

Al Hazaa A, 2000, CLIN CANCER RES, V6, p4542S

[2] Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition [J].

Albanell, J ;

Rojo, F ;

Averbuch, S ;

Feyereislova, A ;

Mascaro, JM ;

Herbst, R ;

LoRusso, P ;

Rischin, D ;

Sauleda, S ;

Gee, J ;

Nicholson, RI ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :110-124

[3]

Anderson N. G., 2000, Breast Cancer Research and Treatment, V64, P32

[4] Tyrosine kinase inhibitors-ZD1839 (Iressa) [J].

Arteaga, CL ;

Johnson, DH .

CURRENT OPINION IN ONCOLOGY, 2001, 13 (06) :491-498

[5] Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer [J].

Barker, AJ ;

Gibson, KH ;

Grundy, W ;

Godfrey, AA ;

Barlow, JJ ;

Healy, MP ;

Woodburn, JR ;

Ashton, SE ;

Curry, BJ ;

Scarlett, L ;

Henthorn, L ;

Richards, L .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) :1911-1914

[6] ANTITUMOR EFFECTS OF DOXORUBICIN IN COMBINATION WITH ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR MONOCLONAL-ANTIBODIES [J].

BASELGA, J ;

NORTON, L ;

MASUI, H ;

PANDIELLA, A ;

COPLAN, K ;

MILLER, WH ;

MENDELSOHN, J .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (16) :1327-1333

[7]

Baselga J, 1999, CLIN CANCER RES, V5, p3735S

[8]

BASELGA J, 1999, AM ASS CANC RES NAT

[9]

Budillon A, 2000, CLIN CANCER RES, V6, p4542S

[10]

Chan KC, 2002, CANCER RES, V62, P122

← 1 2 3 4 5 →